Generex Biotechnology Reports Preliminary Outcomes and Trends from Ongoing Phase III Clinical Trial of Generex Oral-lyn
Findings based on in-process data for subjects that completed the 6-month treatment phase of the study demonstrate several favorable comparisons to injectable insulin
08-Jun-2010 -
Generex Biotechnology Corporation reported preliminary outcomes and trends from the ongoing Phase III pivotal study of Generex Oral-lyn™, the Company’s proprietary oral insulin spray product.
Observations were made regarding insulin antibody levels, weight gain, body mass index, and ...
clinical trials
Generex Biotechnology
insulin